SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp move is drawing attention after Morgan Stanley named it a top pick, citing accelerating AWS growth and AI opportunities; traders are also pointing to Amazons Trainium software announcement as a potential boost to cloud-chip adoption. The reaction is broadly bullish, though some remain cautious about heavy AI capital spending and whether the gains will hold.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports of Lundbecks interest in acquiring Xeris have fueled heavy-volume trading and takeover speculation, though the company has said it is not for sale and no deal is confirmed. Traders are split between expecting further buyer interest and viewing the chatter as unsubstantiated, while some point to Recorlev growth and XP-8121s pipeline potential as standalone reasons for optimism.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are debating whether the move can continue, with some citing short-squeeze potential and others warning of profit-taking, safety concerns around dizziness, and the fact that FDA approval is still pending.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

A cluster of reported open-market purchases by Celsius executives and directors is fueling bullish interest, with traders reading the buying as a sign of confidence and some speculating about a potential Pepsi bid or short covering. Skeptics counter that insider buying does not resolve concerns about weakness in the core Celsius brand, growth, and management execution.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Anticipation of Vicors Q3 earnings is driving discussion after the company raised its sequential growth outlook twice, with traders pointing to higher royalties from its Vertical Power Delivery licensing. Bulls expect the stronger outlook to show up in results, while others are wary of the sharp pullback and volatility despite the guidance increases.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix shares are under pressure as EyePoints failed wet-AMD trial has heightened doubts about TKI-based treatments, prompting traders to question whether those concerns could extend to Oculars AXPAXLI program. Some investors view the selloff as spillover from a competitors results, while others cite clinical uncertainty and the departure of Oculars chief strategy officer as additional concerns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-guided Q3 report and an upbeat 2027 EBITDA outlook are driving CLFs rally. Bulls see improving steel prices and earnings potential, while skeptics warn that debt and the reliance on favorable price forecasts could limit the recovery; traders are also debating whether the move will hold or fade as a sell-the-news rally.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline dominates discussion, with traders pointing to insider selling and upcoming share unlocks alongside concerns about valuation, scaling and reliance on OpenAI amid weakness across AI stocks. Some see the selloff as an oversold buying opportunity and are averaging in, while others expect further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ rebounded as technology and AI stocks recovered from a sharp selloff, with traders debating whether the move marks a durable recovery or a low-volume bull trap. Upcoming megacap earnings and AI spending plans are a key focus for the tech-heavy index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?

ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.

4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.

Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market...

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders...

$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has a marketread more...

Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?

Key PointsAxsome Therapeutics' revenue is growing at a good clip...

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments...

Is Axsome Therapeutics a Buy on the Dip?

Key PointsAxsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth...

AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’

Equity

Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, a Mizuho analyst said new prescriptions for Auvelity rose 32% from July to August. 


Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>First approved in 2022 as an oral treatment for major depression in adults, Auvelity won a second U.S. clearance in April 2026 for agitation linked to Alzheimer’s dementia.</li><li>Management has said peak annual sales for Auvelity could reach $8 billion, split roughly evenly between depression and Alzheimer’s agitation.</li><li>COO Mark Jacobson recently highlighted that Auvelity has no boxed warning for higher death risk in people with dementia, a label that limits the only other approved branded option.</li></ul><p><br>Shares of Axsome Therapeutics (AXSM) rose 6% on Friday after Mizuho analyst Graig Suvannavejh said August prescription data pointed to a strong start for the drug’s newest use.</p><p>Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, he said new prescriptions rose 32% from July, and total prescriptions rose 34%. The stock is now on track to clock its best day since late July, if gains hold.</p><p>“While still early days in the launch, this appears highly indicative of a strong start for Auvelity in ADA,” he wrote. Suvannavejh rates the stock ‘Outperform’ with a $316 price target, implying a potential upside of about 50% from the stock’s last closing price.</p><h2 class="st-heading-2">Why The New Use Matters</h2><p>Auvelity is Axsome’s main product. First approved in 2022 as an oral treatment for major depression in adults, it won a second U.S. clearance in April 2026 for agitation linked to Alzheimer’s dementia — the first non-antipsychotic approved for that condition. Axsome began selling into the new indication in June.</p><p>The Alzheimer’s launch is central to the company’s finances. Auvelity generated $180.3 million in second-quarter sales, up 51% from a year earlier, and made up most of Axsome’s $218.4 million in product revenue. Management has said peak annual sales could reach $8 billion, split roughly evenly between depression and Alzheimer’s agitation.</p><p>Axsome also sells Sunosi for excessive daytime sleepiness tied to narcolepsy or sleep apnea, and Symbravo for acute migraine. Both add sales but remain far smaller than Auvelity.</p><h2 class="st-heading-2">What Management Is Seeing</h2><p>At Cantor Fitzgerald’s conference on Thursday, executives said early doctor feedback matches the trial data: agitation eases quickly, and the drug is well tolerated in a frail group.</p><p>COO Mark Jacobson highlighted that Auvelity has no boxed warning for higher death risk in people with dementia, a label that limits the only other approved branded option, an antipsychotic. That difference, he said, is already generating interest, with the commercial impact expected to build through year-end.</p><p>CFO Nick Pizzie said new prescriptions for patients 65 and older rose 126% after the Alzheimer’s launch. That older Medicare group was about 19% of new starts before approval and is now more than 30%. Most early use is coming from community doctors; nursing homes take longer to bring online, he added.</p><h2 class="st-heading-2">What Investors Will Watch Next</h2><p>The next test for AXSM is whether the August jump in starter doses turns into ongoing use of the full maintenance dose and shows up in third-quarter results, expected in early November. Later this year, Axsome is also due to report late-stage data on solriamfetol — Sunosi’s active ingredient — in binge-eating disorder. It has also started a late-stage study of Auvelity’s compound as a smoking-cessation treatment. A separate narcolepsy candidate, AXS-12, has an FDA decision date of May 1, 2027.</p><h2 class="st-heading-2">How Did AXSM Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AXSM stock jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> has gained 22% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-on-track-for-worst-week-since-last-fall-as-fda-filing-date-for-skin-disease-drug-draws-near/cZtXYWDRBbJ">MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, a Mizuho analyst said new prescriptions for Auvelity rose 32% from July to August. 

Vanguard Small Cap ETF

Vanguard Total Stock Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$156.66
Prev Close	$157.14
Open	$157.68
Dividend Yield	0.00%
50-Day Moving Average	$197.94
Beta	0.73
Avg. Volume	696,952.44
PE Ratio	-41.80

52-Week High	$260.19
52-Week Low	$123.50
Market Capitalization	$8.23B
EPS (Annual)	-$3.68
Price to Book	98.66
Revenue Per Employee	$690,265.95

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXSM Fundamentals